GlassScriptPhysician profile
Sunina Nathoo
NPI 1144667189
$3,367.08
in general payments reported to CMS, 2019-2025
22 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,486 · 2021: $27.05 · 2022: $435 · 2023: $510 · 2024: $768 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,418.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $948.50 | 2019-2024 | |
| Cook Medical LLC | $800.00 | 2019 | |
| Genzyme Corporation | $213.66 | 2022-2024 | |
| Lucid Diagnostics INC. | $140.37 | 2025 | |
| Phathom Pharmaceuticals, INC. | $136.68 | 2024 | Voquezna |
| Janssen Scientific Affairs, LLC | $124.49 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $101.20 | 2022 | |
| Aries Pharmaceuticals, INC. | $100.45 | 2019 | |
| Allergan, INC. | $100.14 | 2019 | |
| Pentax of America, INC. | $99.20 | 2024 | Pentax Medical, C2 Cryoballoon Focal Controller, Inspira |
| Olympus America INC. | $98.86 | 2023 | Evis Exera III Gastrointestinal Videoscope |
| Takeda Pharmaceuticals U.S.A., INC. | $97.15 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $76.41 | 2019-2024 | Stelara |
| Regeneron Healthcare Solutions, INC. | $69.80 | 2023-2024 | Dupixent |
| Braintree Laboratories, INC. | $57.38 | 2024 | Sutab, Suflave |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $50.55 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.76 | 2022 | |
| Coloplast Corp | $23.77 | 2024 | |
| Qol Medical, LLC | $23.39 | 2024 | Sucraid |
| Mallinckrodt Hospital Products INC. | $20.65 | 2024 | Terlivaz |
| Gilead Sciences, INC. | $18.70 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.97 | 2024 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunina Nathoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.